Received Apr 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | UNK | UK211AA | SC / RA |
yf-vax was given with the wrong diluent with no reported adverse event; Initial information received on 23-Mar-2026 regarding an unsolicited valid non-serious case received from a healthcare professional (HCP). This case involves a 21-year-old female patient who received Yellow Fever Vaccine - [Yf-Vax] that was given with the wrong diluent with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s), and family history were not provided. Concomitant medication(s) included Boostrix and Bexsero. On 04-Mar-2026, the patient received a 0.5 mL (once) dose of Yellow Fever Vaccine, solution for injection (batch number: UK211AA, expiry date: 31-Jul-2026) (strength: standard) via subcutaneous route in right arm for immunization (Immunisation) that was given with the wrong diluent (Product preparation error) (latency: same day). It was reported that, "It was not the diluent that came with the product. One of the staff noticed the miscount between the normal saline and yf-vax diluent, so they believed that a staff pulled the sterile water diluent for varicella and other products that was on the table. Three patients received yf-vax in the timeframe of miscount, but they were not sure which one among them got the wrong diluent. Only one patient was administered with the wrong diluent. The coordinator asked about safety concerns and immunity, and whether revaccination was needed. The coordinator mentioned that they might revaccinate all three patients since they were not sure which one received the wrong diluent." Action taken with yellow fever vaccine - us was not reported. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE
Boostrix; Bexsero